Janssen to Codevelop Theravance's TD-1473 in $1B+ Collaboration

Johnson & Johnson’s Janssen Biotech will codevelop Theravance’s TD-1473 and related backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease, the companies said today, through a collaboration that could generate up to $1 billion-plus for Theravance.TD-1473 is a novel, potent, orally administered, and intestinally restricted pan-Janus kinase (JAK) inhibitor that according to Theravance has the potential to treat a variety of inflammat